Abstract
ABSTRACT Introduction Treatment of metastatic carcinoma prostate is hormonal manipulation. Response to the hormone therapy is high but duration is variable. Attempt to develop a marker has clinical relevance and importance to such activity. Aim 1. To show that Serum Chromogranin-A (CgA) at baseline can define the risk population of metastatic Ca Prostate 2. Baseline Serum Chromogranin-A (CgA) may be able to choose patient who may require early non-hormonal interventions. Method Study was done in a period of 2005 to 2010. 160 patients of Metastatic Ca Prostate who had no chemotherapy or hormonal therapy were included. All patients were staged by Bone Scan, CT scan, and Trans Rectal Ultrasound. Routine biochemistry was done. Serum Chromogranin-A (CgA) was assayed by immune-fluorescence microscopy (IFM) and immuno chemiluminometer (ICMA). PSA was assayed by immuno chemiluminometer (ICMA). Gleason's score was obtained from biopsy report. All patients were serially followed up at three monthly intervals. Statistical analysis, descriptive analysis for population was used. Patients were stratified on the basis of Gleason's score >7 or 10 or Results Out of the 160 patients at the end of 3 years surveillance 59 had progressed; 8 patients with Gleason's score 7 out of 62 had progressed and 51 out of 96 patients with Gleason's score >7 had progressed. 14 patients out of 40 with PSA 100 are alive while 75% of patients (120 patients) with CgA Conclusion a) CgA assay at metastatic presentation seems like an important marker for prognosis b) Needs to be validated in a larger study c) May be a marker in choosing early chemotherapy d) Neuroendocrine markers in early ca prostate should be studied and biopsy should be stratified in the presence or absence of neuroendocrine differentiation. Keywords Metastatic Ca Prostate; Serum Chromogranin-A; Disease progression Disclosure All authors have declared no conflicts of interest.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
